ENDPOINTS

Arcus touts early kidney cancer data as Gilead declines option

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move forward into additional studies. At the same time, Gilead passed on its option to ...

Feb 18, 2025 - 17:35
 0
Arcus touts early kidney cancer data as Gilead declines option
Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move forward into additional studies. At the same time, Gilead passed on its option to ...
Read More

Tags:

Previous Article

Strange corkscrew burrows and other unexpected structures discovered 4.7 miles d...

Next Article

T&E and 70+ Aviation Industry Actors Call Upon the European Commission to Suppor...

Related Posts

Kojin Therapeutics shuts down, citing lack of investor interest and complex science

Kojin Therapeutics shuts down, citing lack of investor ...

Feb 14, 2025  0

Trump’s picks for NIH, CMS say they’ll unload industry investments

Trump’s picks for NIH, CMS say they’ll unload industry ...

Feb 20, 2025  0

First meeting of CDC vaccine advisors in the Kennedy era is postponed

First meeting of CDC vaccine advisors in the Kennedy er...

Feb 20, 2025  0